GSTC.US AngioSoma Inc
- Market cap
- USD 124K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2024.
Is GSTC.US undervalued?
Graham numberThe Graham number of AngioSoma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AngioSoma Inc fundamental analysis
No fundamental analysis for AngioSoma Inc yet.
AngioSoma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AngioSoma Inc
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, engages in the provision of patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases in the United States. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in New York, New York.
Full company profileAngioSoma Inc financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
AngioSoma Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 97.3K | 42.2K | 59.2M | 73.8M | 890.00 | 425.00 | 77.00 | - | - | - | - |
| Gross Profit | 77.0K | 24.5K | 36.9M | 49.7M | 683.00 | 271.00 | -37.6K | -2.41K | - | - | - |
| Operating Income | -458K | -698K | -155K | -461K | -351K | -316K | -304K | -9.09M | -1.27M | -1.27M | -739K |
| EBITDA | -426K | -676K | -2.78M | -536K | -713K | -314K | -302K | -9.51M | -1.42M | -1.27M | - |
| Net Income | -1.25M | -1.09M | -3.29M | -1.68M | -817K | -675K | -780K | -9.67M | -1.64M | -1.49M | -761K |
| EPS | -7.50 | -0.66 | -0.12 | -0.04 | -0.01 | -0.01 | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 478K | 322K | 17.3K | 24.6K | 125K | 142K | 89.9K | 5.96K | 9.92K | - | 83.9K |
| Total Liabilities | 582K | 310K | 860K | 649K | 995K | 828K | 749K | 732K | 1.20M | 1.43M | 1.71M |
| Shareholders' Equity | -104K | 12.6K | -843K | -624K | -871K | -685K | -659K | -726K | -1.19M | - | -1.62M |
| Cash & Short-term Investments | 1.21K | 5.69K | 5.85K | 14.1K | 91.6K | 100K | 81.4K | 5.96K | 6.37K | - | 41.00 |
| Total Debt | 257K | 110K | 523K | 88.8K | 285K | 114K | 155K | 106K | 20.0K | 360K | 329K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -311K | -402K | -30.0K | -53.7K | -180K | -260K | -240K | -751K | -327K | -206K | -96.0K |
| Capital Expenditure | 105K | 14.3K | 59.9M | 1.41K | 1.41K | 1.41K | 1.78K | 0.00 | 5.00 | 0.00 | 4.00 |
| Free Cash Flow | -416K | -417K | -30.0K | -53.7K | -182K | -260K | -242K | -751K | -327K | -206K | -96.0K |
| Ratios | |||||||||||
| ROE | - | -8,591.1% | - | - | - | - | - | - | - | - | - |
| ROA | -260.7% | -336.9% | -19,068.9% | -6,842.3% | -654.9% | -474.7% | -867.3% | -162,235.4% | -16,542.7% | - | -907.2% |
| Net Profit Margin | -1,280.2% | -2,576.3% | -5.6% | -2.3% | -91,797.8% | -158,823.5% | -1,012,715.6% | - | - | - | - |
| Debt to Equity | - | 8.72x | - | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
AngioSoma Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 1.60M | 0.02 | - |
| 2018 | - | - | - |
| 2017 | USD 19.3M | 0.50 | - |
| 2016 | USD 3.62M | 0.14 | - |
| 2015 | USD 14.5M | 8.80 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:100 on Jun 30, 2015.
Who owns AngioSoma Inc
Ownership data of AngioSoma Inc is not available yet.
AngioSoma Inc company profile
- Company name
- AngioSoma Inc
- Ticker
- GSTC.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- September
- Address
- 1280 Lexington Avenue, New York, NY, United States, 10028
- Phone
- 509 531 1671
- Website
- globestartherapeutics.com
About AngioSoma Inc
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, engages in the provision of patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases in the United States. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in New York, New York.
AngioSoma Inc management
3- Mr. James C. KatzaroffPresident, CEO, Secretary, Principal Executive Officer & Chairman of the Board · born 1957
- Ms. Brooke GreenwaldChief Marketing Officer
- Mr. David CroomExecutive Vice President